Clinical researchers from Hospital Dipreca in Santiago, Chile, Gastro Obeso Center in São Paulo, Brazil, Carolinas Medical Center in Charlotte, North Carolina, and the Billings Clinic in Billings, Montana conducted a multi-center study of the EndoBarrier gastrointestinal liner from GI Dynamics (Lexington, Massachusetts) on patients with type II diabetes. The trial demonstrated overall positive results, and Dr. Robert Jasmer from UCSF reviewed the findings of the study at MedPageToday.
In a small pilot study, fasting plasma glucose levels for patients who received the duodenal-jejunal bypass liner (EndoBarrier) fell 55 mg/dL, while levels among those who had a sham procedure rose 42 mg/dL (P≤0.05), according to Christopher Sorli, MD, of the Billings Clinic in Billings, Mont., and colleagues.
But differences in this measure of glycemic control did not remain significant after the 24 weeks of the study were completed. Also, the study was scheduled to run for 52 weeks but too many patients had to have the device removed because of pain or anchor migration before that time.
Read on at MedPage Today: Intestinal Sleeve May Improve Glycemic Control
Press release: GI Dynamics’ EndoBarrier™ Gastrointestinal Liner Demonstrates Safety and Efficacy in Pre-surgical Weight Loss …
Abstract in Diabetes Technology & Therapeutics: Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes
Link: EndoBarrier Technology…
Flashbacks: EndoBarrier, an Internal Condom, Gets Positive Results in Diabetic Clinical Trial ; Eat Away, Just Don’t Digest